EA201000717A1 - Молекулы и способы, предназначенные для модуляции компонента системы комплемента - Google Patents

Молекулы и способы, предназначенные для модуляции компонента системы комплемента

Info

Publication number
EA201000717A1
EA201000717A1 EA201000717A EA201000717A EA201000717A1 EA 201000717 A1 EA201000717 A1 EA 201000717A1 EA 201000717 A EA201000717 A EA 201000717A EA 201000717 A EA201000717 A EA 201000717A EA 201000717 A1 EA201000717 A1 EA 201000717A1
Authority
EA
Eurasian Patent Office
Prior art keywords
molecules
complement system
modulating component
methods intended
methods
Prior art date
Application number
EA201000717A
Other languages
English (en)
Inventor
Байджан Этимад-Гилбертсон
Брайдон Чарлз Гуилд
Марк Тейлор Китинг
Ён-Ин Ким
Ллойд Б. Кликстейн
Дмитри Михайлов
Мариуш Милик
Майкл Рогуска
Игор Сплавски
Кехао Чжао
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201000717A1 publication Critical patent/EA201000717A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В заявке описаны композиции, которые связываются с эпитопами С3b, и способы применения указанных композиций.
EA201000717A 2007-11-02 2008-10-31 Молекулы и способы, предназначенные для модуляции компонента системы комплемента EA201000717A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98495107P 2007-11-02 2007-11-02
PCT/EP2008/064809 WO2009056631A2 (en) 2007-11-02 2008-10-31 Molecules and methods for modulating complement component

Publications (1)

Publication Number Publication Date
EA201000717A1 true EA201000717A1 (ru) 2010-12-30

Family

ID=40343498

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000717A EA201000717A1 (ru) 2007-11-02 2008-10-31 Молекулы и способы, предназначенные для модуляции компонента системы комплемента

Country Status (21)

Country Link
US (1) US20090175875A1 (ru)
EP (1) EP2207807A2 (ru)
JP (1) JP2011503024A (ru)
KR (1) KR20100067681A (ru)
CN (1) CN101848937A (ru)
AR (1) AR069130A1 (ru)
AU (1) AU2008320820A1 (ru)
CA (1) CA2703911A1 (ru)
CL (1) CL2008003241A1 (ru)
CO (1) CO6270341A2 (ru)
CR (1) CR11361A (ru)
EA (1) EA201000717A1 (ru)
IL (1) IL204722A0 (ru)
MA (1) MA31795B1 (ru)
MX (1) MX2010004833A (ru)
PE (1) PE20091388A1 (ru)
SV (1) SV2010003556A (ru)
TN (1) TN2010000169A1 (ru)
TW (1) TW200924795A (ru)
WO (1) WO2009056631A2 (ru)
ZA (1) ZA201002335B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
EP2222846B1 (en) * 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
EP2207808B1 (en) 2007-11-02 2013-05-08 Novartis AG Improved nogo-a binding molecules and pharmaceutical use thereof
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
EP2569332B1 (en) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
WO2012075023A2 (en) 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
CN105683759B (zh) 2013-08-07 2019-03-29 瑞颂医药公司 非典型溶血性尿毒综合征(aHUS)生物标志物蛋白
WO2015105973A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
US10568568B2 (en) * 2014-08-27 2020-02-25 Capnia, Inc. Methods for immune globulin administration
MX2018007392A (es) 2015-12-23 2018-08-15 Greenovation Biotech Gmbh Polipeptidos para inhibir la activacion del complemento.
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5932217A (en) * 1991-05-03 1999-08-03 The Rockefeller University Peptides which inhibit adhesion between leukocytes and endothelial cells
AU6397796A (en) * 1995-06-29 1997-01-30 Medical Biology Institute Method for identifying peptides that affect protein-protein interactions and complement-modulating peptides
AU2002251366A1 (en) * 2001-05-02 2002-11-11 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
US7042716B2 (en) * 2003-08-25 2006-05-09 Simon John Edward Shearman Ergonomic pull-out computer housing
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
AU2006304605A1 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US7327547B1 (en) * 2006-01-20 2008-02-05 Epstein Barry M Circuit element and use thereof
MX2009013082A (es) * 2007-06-07 2010-01-15 Genentech Inc Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.

Also Published As

Publication number Publication date
WO2009056631A3 (en) 2009-08-20
US20090175875A1 (en) 2009-07-09
SV2010003556A (es) 2011-03-23
CL2008003241A1 (es) 2009-07-31
JP2011503024A (ja) 2011-01-27
MA31795B1 (fr) 2010-10-01
TW200924795A (en) 2009-06-16
TN2010000169A1 (en) 2011-11-11
CR11361A (es) 2010-06-01
KR20100067681A (ko) 2010-06-21
CN101848937A (zh) 2010-09-29
IL204722A0 (en) 2010-11-30
AU2008320820A1 (en) 2009-05-07
AR069130A1 (es) 2009-12-30
MX2010004833A (es) 2010-05-27
WO2009056631A2 (en) 2009-05-07
CA2703911A1 (en) 2009-05-07
EP2207807A2 (en) 2010-07-21
ZA201002335B (en) 2011-02-23
CO6270341A2 (es) 2011-04-20
PE20091388A1 (es) 2009-09-24

Similar Documents

Publication Publication Date Title
EA201000717A1 (ru) Молекулы и способы, предназначенные для модуляции компонента системы комплемента
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201890315A1 (ru) Молекулы антител, связывающие cd22
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA201400579A1 (ru) Антитела к il-36r
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201591474A1 (ru) Модуляторы метил-модифицирующих ферментов, композиции и их применение
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA200802168A1 (ru) Гуманизированное антитело к с-kit
AR064456A1 (es) Anticuerpos cd 44
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
EA201300530A1 (ru) Антитела к il-23
EA201100523A1 (ru) Соединения сульфонила, которые селективно модулируют рецептор св2